Covid News LIVE Updates

News Desk, News on West Bengal : - Covid News LIVE Updates | We need to stop second rush of Covid by making conclusive strides: PM Modi after meet with CMs 

Covid News LIVE Updates: The total number of COVID-19 antibody dosages controlled in the nation has crossed 3.48 crore, the Union wellbeing service said. 

Covid News LIVE Updates: Today is the 357th day since India executed a cross country lockdown to help check the novel Covid pandemic. India recorded 28,903 new COVID-19 cases, enlisting in excess of 20,000 cases for the seventh day straight, taking the disease count past 1.14 crore, the Union wellbeing service said. 

The absolute cases in the nation rose to 1,14,38,734, while the loss of life expanded to 1,59,044. The all out dynamic caseload has expanded to 2,34,406. The quantity of individuals who have recovered from the sickness flooded to 1,10,45,284.

All around the world, more than 12.03 crore individuals have been contaminated by the Covid and 27.88 lakh have kicked the bucket up until this point. India has started the second period of the immunization drive in which everybody over 60 years old and those more than 45 years with comorbidities will actually want to get the COVID-19 antibody.

India's controller has allowed confined crisis use endorsement for two antibodies - Covishield and Covaxin. The aggregate number of COVID-19 immunization portions controlled in India has crossed 3.48 crore, as indicated by the Union Health Ministry.

Most of Oxford's 50 million rupees will go to India first: the head of the serum

Most of Oxford's 50 million rupees will go to India first: the head of the serum If the Oxford-AstraZeneca vaccine is approved, India will get most of its first 50 million doses. This was stated on Monday by Adar Punawala, Chief Executive Officer (CEO) of Serum Institute of India, a vaccine manufacturer in the country. "Most of the 50 million doses of the Oxford-AstraZeneca vaccine Covishield will be given to India, at least for the first month," Punawala told reporters on Monday. Due to the fact that it needs the approval of the World Health Organization (WHO) for its export to other countries, India will get most of the dose of the vaccine, said the head of the serum. 172 countries around the world have teamed up with corona vaccine manufacturers to launch an initiative called CoVAX. It is expected that it will be easier to provide vaccines as part of this initiative. "We have agreements with other Caucasus countries," he said. However, vaccines cannot be exported to other countries without the approval and license of HU. So India will get the first cove shield. " The head of Siram claims that his company has already prepared 4 to 5 crore ‘Covishields’. In addition, a target has been set to increase the production of the vaccine to 100 million by next March. And by next July, his company will be able to produce another 300 million Covishields. "We hope to get the vaccine approved in India in the next few days," Punawala said. After that, it is up to the Indian government to determine how much of the vaccine is needed and how quickly it can be passed on to the public. " Punawala also said that all the information on Kovishielde had been submitted to the relevant licensing bodies in Britain and India. "The regulators are scrutinizing all the information on the ticker trial," he said. There is no reason to worry about this. ”However, Punawala also warned about the corona vaccine. According to him, "the first six months of next year will see less vaccines around the world." Although there is nothing to do with it. However, this situation may change between August and September 2021. Because in that time countless vaccine manufacturers around the world will start supplying it. " Apart from Covishield, India is also in the race to launch Biotech and Pfizer vaccines in the country. Pascal Suriot, CEO of AstraZeneca, claims that ‘covishields’ are as effective as Pfizer and Mordana in building immunity against corona in the human body. Suriot also claims that it is 95 percent effective. However, AstraZeneca has not yet been able to provide any evidence.

Conversely, an internal report released last month on a trial of the third phase of the vaccine found that Covishield had an 80 per cent effectiveness. Again, after one half dose, another full dose has increased its effectiveness by 90 percent. On the other hand, in the case of Pfizer it is 95 percent and in the case of Modern Dose it is 94.5 percent.

The Indian government had earlier said that it would cost Rs 250 per dose of Kovishield in the country. As a result, Covishield, which is cheaper than other vaccines, is thought to be a few steps ahead of the competition in the Indian market if there is adequate storage infrastructure and supply chain.